M&T Bank Corp Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

M&T Bank Corp acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,700 shares of the company's stock, valued at approximately $667,000.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after acquiring an additional 21,133 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares during the last quarter. Hood River Capital Management LLC increased its position in shares of Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after purchasing an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KRYS. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Wednesday, May 7th. Guggenheim reduced their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, June 24th. Finally, Citigroup reiterated a "neutral" rating and set a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $213.75.

Krystal Biotech Trading Down 1.8%

Krystal Biotech stock traded down $2.66 during mid-day trading on Friday, hitting $147.49. The company had a trading volume of 303,976 shares, compared to its average volume of 287,068. The stock's 50 day moving average price is $136.57 and its two-hundred day moving average price is $155.93. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The company has a market capitalization of $4.26 billion, a PE ratio of 35.45 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 13,435 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 49,800 shares of company stock worth $7,487,943 over the last 90 days. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).